Specialization
CRISPR & Isothermal
Deep expertise in the molecular chemistries that enable faster, simpler, and more accessible detection.
Design → Validate → Transfer → Market
Accelerating Molecular Innovation
We build the molecular detection technologies behind next-generation diagnostics—from CRISPR and isothermal amplification to multiplex real-time PCR—and turn them into validated, market-ready products alongside diagnostic innovators.
0-plex
Real-time PCR panel validated and transferred to a commercial partner
<0 copies
Per-reaction limit of detection demonstrated in multiplex
0–0 weeks
Typical timeline for an analytical validation program
Your IP
Foreground IP generated through your program remains yours.
Who we are
We develop the technology. Then we develop it with you.
Amplera develops molecular detection technologies for next-generation diagnostics—from CRISPR and isothermal amplification to multiplex real-time PCR and computational assay design.
We bring these technologies into partner programs, aligned to your timeline, documentation, and product goals.
You are not buying a set of experimental steps. You are building on deep molecular expertise.
Our scientist-led team is supported by advisors across CRISPR, bioinformatics, regulatory strategy, and clinical validation, with one named scientific lead accountable for every program.
Accountability
One accountable team
Guiding your program from concept and assay development through validation and product transfer.
Ownership
Your foreground IP stays yours
IP generated specifically through your program remains yours, with ownership defined clearly from the outset.
Two ways to work with Amplera
Build with us. Or build on what we develop.
We develop molecular diagnostics for partners under contract and advance our own platforms independently.
Your program, your IP. Our platforms, our innovation.
Development under contract.
From assay development and optimization to analytical validation, regulatory documentation, and technology transfer—we deliver to your timeline, documentation standards, and product requirements.
Your foreground IP stays yours.
For diagnostics and reagent companies, established manufacturers, pharma, public health programs, and companies entering India.
See what we deliverA portable CRISPR platform.
We are developing a single-workflow molecular test to identify priority bacterial pathogens and resistance genes from a single sample—without a thermal cycler or conventional laboratory infrastructure.
For clinical collaborators, public health programs, research funders, and investors. Development-stage technology; performance claims have not yet been clinically verified.
See the platformYour program, your IP. Our research, our IP. We keep partner-funded development and Amplera-funded research clearly separated, with ownership defined transparently from the outset.
How we work
Every stage has a clear objective, defined acceptance criteria, and a decision to move forward.
Five stages. Milestone-driven, with predefined QC acceptance criteria at every stage—so issues are identified early, not at the end.
01
Requirements
02
Design & Feasibility
03
Development & Optimization
04
Validation
05
Transfer & Delivery
Regulatory and Quality run alongside, from stage 02 through delivery
Typical validation sprint: 4 to 12 weeks.
Case study · Aquaculture health
Four pathogens. One reaction. One run.
Targets
0+IAC
Four pathogen targets plus internal amplification control.
Workflow
0run
One sample. One multiplex reaction.
Sensitivity
<0copies
Limit of detection below 10 copies per reaction.
Ownership
Client-owned
Foreground IP retained by the client.
A shrimp-health company needed to screen for multiple high-impact pathogens with overlapping clinical signs. We designed a probe-based four-target multiplex real-time PCR assay with an internal amplification control, optimized sample preparation across tissue, soil, and water matrices, and carried the assay through analytical validation.
Why Amplera
We don’t just develop assays. We develop what comes next.
| Fragmented Development | Amplera | |
|---|---|---|
| What matters | Multiple specialized providers | One integrated program |
| Development | Handoffs between teams | One named scientific lead |
| Validation | Coordination across providers | Defined, milestone-driven sprints |
| IP | Contract-dependent | Your foreground IP stays yours |
If diagnostics development is your permanent core, build it in-house. If you have one program, one deadline, and a product to move, work with Amplera.
Design to bench: 2–4 weeks · Validation sprint: 4–12 weeks · Accountability: One named scientific lead, end to end.
Who we serve
Built for innovators across the diagnostics value chain.
Diagnostics & reagent startups
Reach a validated, market-ready product without building full in-house development capacity.
Established manufacturers
Extend development capacity and accelerate new assay pipelines without disrupting core operations.
Companies entering India
Navigate local validation, technology transfer, and regulatory requirements, including CDSCO pathways.
Pharma & biotech
Develop companion diagnostics, biomarker assays, and molecular testing workflows.
Academic & clinician innovators
Translate promising research assays into robust, manufacturable diagnostic products.
Government & public health
Develop accessible, scalable molecular assays designed for cost-effective deployment.
Get started
Let’s build your assay.
Have a target, sample type, or diagnostic challenge? Tell us what you’re working on. We’ll respond within one business day with an initial feasibility assessment, a proposed development path, and an indicative timeline.
Looking to advance our CRISPR platform rather than start a development program? Talk to us about partnering
Your science stays confidential. We can work under your NDA or provide ours before any technical discussion.